Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

NCT05029609 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Withdrawn due to business reasons

Conditions

Primary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Multiple Sclerosis

Interventions

DRUG: Intranasal Foralumab Solution
DRUG: Placebo

Sponsor

Tiziana Life Sciences LTD